ClinicalTrials.gg
CompletedNCT00660660Updated Mar 2, 2015Results posted

Local Phase IV, Gastroesophageal Reflux Disease (GERD) Sleep Study US

A Phase 4 interventional study of Esomeprazole and Placebo in Gastroesophageal Reflux Disease, sponsored by AstraZeneca. Completed at 45 sites in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2015-03-02.

Sponsored by AstraZeneca · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
276
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 67 studies testing esomeprazole in Gastroesophageal Reflux — 1 open to participants now, 1 under way, none of them phase 3. Esomeprazole · Gastroesophageal Reflux.

Enrollment
23rd of 66
276 · median 125
Started
2008
with 5 others
Phase 4
28 of 67
none open now
Registered
41st of 67
by date
Lead sponsor
36 of 67
AstraZeneca

Among the 67 studies testing esomeprazole in Gastroesophageal Reflux, this one is the 23rd largest by enrollment of the 66 interventional ones that give a count, is one of 6 that started in 2008, is one of 28 in phase 4, and was the 41st registered.

Gastroesophageal Reflux

1,215 studies on the registry are indexed under Gastroesophageal Reflux; 204 are open to participants now.

Browse Gastroesophageal Reflux studies →

Open to participants now

1 of the 67 studies testing esomeprazole in Gastroesophageal Reflux is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About esomeprazole

Esomeprazole: first FDA approval 2001 (NEXIUM), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 134 Gastroesophageal Reflux studies recruiting now, 58 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies testing esomeprazole in Gastroesophageal Reflux, or all of them as a file.
02

Study summary

The purpose of this research study is to compare the safety and effectiveness (how well the medicine works) of esomeprazole (study drug) to placebo (a capsule that does not contain any medication) taken daily in relieving nighttime heartburn and problems sleeping in patients with gastroesophageal reflux disease (GERD).

03

Conditions studied

  • Gastroesophageal Reflux Disease

Keywords

  • GERD
  • Esophageal Reflux
  • Gastro-Esophageal Reflux
  • Regurgitation
  • Gastric
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Prior to the run-in period, a history of heartburn or acid regurgitation for 3 months or longer or any history of EE;
  • Prior to the run-in period, nighttime heartburn averaging at least 2 or 3 times per week;
  • Prior to the run-in period, a history of sleep disturbances associated with GERD for 1 month or more;

Exclusion criteria

Exclusion Criteria:

  • Any condition other than GERD that is either the primary cause of, or a significant contributor to, the patient's sleep disturbance
  • Sleep medication (including over-the-counter), antihistamine, benzodiazepine, or anti-anxiety medication use that has not been stable (either in dose or regularity) for at least 3 months or is not expected to remain stable during the patient's participation in the study. Patients on a stable regimen, whose regimen is also expected to remain stable throughout the study, are eligible for participation;
  • Proton Pump Inhibitor (PPI) use within 1 week prior to Screening. The only allowable acid modifying rescue medication is GELUSIL® during the run-in period. Only study medication and rescue medication (GELUSIL®) is allowed during the treatment period for treatment of acid mediated symptoms
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
276 participants (actual)

Study arms

  • Experimental
    Nexium 20mg

    Nexium 20 mg administered once daily as 22.3 mg of esomeprazole magnesium hydrate

    Drug: Esomeprazole

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Nexium 20 mg administered once daily as 22.3 mg of esomeprazole magnesium hydrate

    Also known as: Nexium

  • DrugPlacebo

    once daily

06

What researchers measure

Primary outcomes

  1. Percentage of Patients With Relief of Nighttime Heartburn During the Last 7 Days of the Study.

    Relief of nighttime heartburn on patient's last 7 days in the study. Relief was defined as a daily diary card response of "none" or 0, on at least 6 of 7 days, allowing for one "mild" or 1 response. Diary card scale (none, mild, moderate, severe).

    Time frame: Days 21- 28 (for early dropouts the last 7 days staying in the study)

Secondary outcomes

  1. Change in Mean (Average) Pittsburgh Sleep Quality Index (PSQI) Scores From Baseline

    To assess the impact of treatment as measured by: Change in global Pittsburgh Sleep Quality Index (PSQI) scores from baseline to week 4. Scale details -'Scoring ranged from 0, "no difficulty" to 3, "severe difficulty." Items were grouped into 7 component scores. The 7 components were then summed to yield a global PSQI score. Global scores \>5 were considered to meet the criteria of sleep disturbance.

    Time frame: Baseline and 4 weeks

  2. Achievement of Developer-defined Good Sleep

    To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on sleep disturbances associated with Gastroesophageal reflux disease (GERD), as measured by achievement of (yes/no) developer-defined good sleep (global Pittsburgh Sleep Quality Index - PSQI score ≤5) at Week 4.

    Time frame: 4 weeks

  3. Number of Patients With Complete Resolution of Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD) After 1 Week of Treatment.

    The assessment was based on patients registrations of the answers "Yes" or "No" to the question: "Did you have trouble sleeping last night due to your heartburn or other symptoms of Gastroesophageal Reflux Disease (GERD)?". Complete resolution of GERD-related sleep disturbances was defined as a daily diary response of "No" on 7 consecutive days.

    Time frame: 1 week

  4. Number of Patients With Complete Resolution of Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD) After 2 Weeks of Treatment.

    The assessment was based on patients registrations of the answers "Yes" or "No" to the question: "Did you have trouble sleeping last night due to your heartburn or other symptoms of Gastroesophageal Reflux Disease (GERD)?". Complete resolution of GERD-related sleep disturbances was defined as a daily diary response of "No" on 14 consecutive days.

    Time frame: 2 weeks

  5. Number of Patients With Complete Resolution of Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD) After 4 Weeks of Treatment.

    The assessment was based on patients registrations of the answers "Yes" or "No" to the question: "Did you have trouble sleeping last night due to your heartburn or other symptoms of GERD?". Complete resolution of Gastroesophageal Reflux Disease (GERD)-related sleep disturbances was defined as a daily diary response of "No" on 7 consecutive days during 4 weeks of treatment.

    Time frame: 4 weeks

  6. Number of Patients With Complete Resolution of Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD) on the Patient's Last 7 Days in the Study.

    To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on sleep disturbances associated with Gastroesophageal Reflux Disease (GERD), as measured by: Complete resolution of sleep disturbances on the patient's last 7 days in the study.

    Time frame: Days 21- 28 (for early dropouts the last 7 days staying in the study)

  7. Number of Patients With Relief of Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD) After 1 Week of Treatment

    The assessment was based on patients registrations of the answers "Yes" or "No" to the question: "Did you have trouble sleeping last night due to your heartburn or other symptoms of Gastroesophageal Reflux Disease (GERD)?". Relief of sleep disturbances associated with GERD was defined as a daily diary response of "Yes" on not more than 2 of 7 consecutive days.

    Time frame: 1 week

  8. Number of Patients With Relief of Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD) After 2 Weeks of Treatment

    The assessment was based on patients registrations of the answers "Yes" or "No" to the question: "Did you have trouble sleeping last night due to your heartburn or other symptoms of Gastroesophageal Reflux Disease (GERD)?". Relief of sleep disturbances associated with GERD was defined as a daily diary response of "Yes" on not more than 2 of 7 consecutive days.

    Time frame: 2 weeks

  9. Number of Patients With Relief of Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD) After 4 Weeks of Treatment

    The assessment was based on patients registrations of the answers "Yes" or "No" to the question: "Did you have trouble sleeping last night due to your heartburn or other symptoms of Gastroesophageal Reflux Disease (GERD)?". Relief of sleep disturbances associated with GERD was defined as a daily diary response of "Yes" on not more than 2 of 7 consecutive days.

    Time frame: 4 weeks

  10. Percentage of Patients With Relief of Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD) on the Patient's Last 7 Days in the Study.

    The assessment was based on patients registrations of the answers "Yes" or "No" to the question: "Did you have trouble sleeping last night due to your heartburn or other symptoms of Gastroesophageal Reflux Disease (GERD)?". Relief of sleep disturbances associated with GERD was defined as a daily diary response of "Yes" on not more than 2 of 7 consecutive days.

    Time frame: Days 21- 28 (for early dropouts the last 7 days staying in the study)

  11. Percentage of Days Without Gastroesophageal Reflux Disease (GERD)-Related Sleep Disturbances During the 4 Week Period

    To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on sleep disturbances associated with Gastroesophageal Reflux Disease (GERD)as measured by: Percent of days without sleep disturbances after 4 weeks of treatment. Each morning of the study, patients registered their answer "Yes" or "No" to the question, "Did you have trouble sleeping last night due to your heartburn or other symptoms of GERD?" in the diary card.'

    Time frame: 4 weeks

  12. Number of Days to First Relief of Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD) During the 4 Week Treatment Period

    The assessment was based on patients registrations of the answers "Yes" or "No" to the question: "Did you have trouble sleeping last night due to your heartburn or other symptoms of Gastroesophageal Reflux Disease (GERD)?". Relief of sleep disturbances associated with GERD was defined as a daily diary response of "Yes" on not more than 2 of 7 consecutive days, and 'days to first relief' was defined as the first day of the 7 days that reached relief of sleep disturbance.

    Time frame: 4 weeks

  13. Number of Days to Resolution of Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD) During the 4 Week Treatment Period

    The assessment was based on patients registrations of the answers "Yes" or "No" to the question: "Did you have trouble sleeping last night due to your heartburn or other symptoms of Gastroesophageal Reflux Disease (GERD)?". Relief of sleep disturbances associated with GERD was defined as a daily diary response of "Yes" on not more than 2 of 7 consecutive days.

    Time frame: 4 weeks

  14. Number of Days to First Complete Resolution of Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD) During the 4 Week Treatment Period

    To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on sleep disturbances associated with Gastroesophageal Reflux Disease (GERD), as measured by: Days to complete resolution of sleep disturbance. Days to complete resolution of sleep disturbances associated with GERD was defined as the number of days until the first day of the first 7-consecutive-day period during which the patient's daily diary response was "No" (did not have trouble sleeping due to GERD symptoms).'

    Time frame: 4 weeks

  15. Percentage of Patients With Complete Resolution of Daytime Heartburn After 1 Week of Treatment

    To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on heartburn, as measured by: Complete resolution of daytime heartburn after 1 week of treatment. Results based on MITT population with available data for this outcome measure. Complete resolution of daytime, nighttime, and 24-hour heartburn was defined as a daily diary response of "None" on 7 consecutive days.

    Time frame: 1 week

  16. Percentage of Patients With Complete Resolution of Daytime Heartburn After 2 Weeks of Treatment

    To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on heartburn, as measured by: Complete resolution of daytime heartburn after 2 weeks of treatment. Complete resolution of daytime, nighttime, and 24-hour heartburn was defined as a daily diary response of "None" on 7 consecutive days.

    Time frame: 2 weeks

  17. Percentage of Patients With Complete Resolution of Daytime Heartburn After 4 Weeks of Treatment

    To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on heartburn, as measured by: Complete resolution of daytime heartburn after 4 weeks of treatment. Complete resolution of daytime, nighttime, and 24-hour heartburn was defined as a daily diary response of "None" on 7 consecutive days.

    Time frame: 4 weeks

  18. Percentage of Patients With Complete Resolution of Daytime Heartburn on the Patient's Last 7 Days in the Study

    To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on heartburn, as measured by: Complete resolution of daytime heartburn on the patient's last 7 days in the study. Complete resolution of daytime, nighttime, and 24-hour heartburn was defined as a daily diary response of "None" on 7 consecutive days.

    Time frame: Days 21- 28 (for early dropouts the last 7 days staying in the study)

  19. Percentage of Patients With Complete Resolution of Nighttime Heartburn After 1 Week of Treatment.

    To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on heartburn, as measured by: Complete resolution of nighttime heartburn after 1 week of treatment. Complete resolution of daytime, nighttime, and 24-hour heartburn was defined as a daily diary response of "None" on 7 consecutive days.

    Time frame: 1 week

  20. Percentage of Patients With Complete Resolution of Nighttime Heartburn After 2 Weeks of Treatment

    To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on heartburn, as measured by: Complete resolution of nighttime heartburn after 2 weeks of treatment. Complete resolution of daytime, nighttime, and 24-hour heartburn was defined as a daily diary response of "None" on 7 consecutive days.

    Time frame: 2 weeks

  21. Percentage of Patients With Complete Resolution of Nighttime Heartburn After 4 Weeks of Treatment

    To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on heartburn, as measured by: Complete resolution of nighttime heartburn after 4 weeks of treatment. Complete resolution of daytime, nighttime, and 24-hour heartburn was defined as a daily diary response of "None" on 7 consecutive days.

    Time frame: 4 weeks

  22. Percentage of Patients With Complete Resolution of Nighttime Heartburn on the Patient's Last 7 Days in the Study.

    To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on heartburn, as measured by: Complete resolution of nighttime heartburn on the patient's last 7 days in the study. Complete resolution of daytime, nighttime, and 24-hour heartburn was defined as a daily diary response of "None" on 7 consecutive days.

    Time frame: Days 21- 28 (for early dropouts the last 7 days staying in the study)

  23. Percentage of Patients With Complete Resolution of 24-hour Heartburn After 1 Week of Treatment

    To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on heartburn, as measured by: Complete resolution of 24-hour heartburn after 1 week of treatment. Complete resolution of daytime, nighttime, and 24-hour heartburn was defined as a daily diary response of "None" on 7 consecutive days.

    Time frame: 1 week

  24. Percentage of Patients With Complete Resolution of 24-hour Heartburn After 2 Weeks of Treatment

    To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on heartburn, as measured by: Complete resolution of 24-hour heartburn after 2 weeks of treatment. Complete resolution of daytime, nighttime, and 24-hour heartburn was defined as a daily diary response of "None" on 7 consecutive days.

    Time frame: 2 weeks

  25. Percentage of Patients With Complete Resolution of 24-hour Heartburn After 4 Weeks of Treatment

    To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on heartburn, as measured by: Complete resolution of 24-hour heartburn after 4 weeks of treatment. Complete resolution of daytime, nighttime, and 24-hour heartburn was defined as a daily diary response of "None" on 7 consecutive days.

    Time frame: 4 weeks

  26. Percentage of Patients With Complete Resolution of 24-hour Heartburn on the Patient's Last 7 Days in the Study

    To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on heartburn, as measured by: Complete resolution of 24-hour heartburn on the patient's last 7 days in the study. Complete resolution of daytime, nighttime, and 24-hour heartburn was defined as a daily diary response of "None" on 7 consecutive days.

    Time frame: Days 21- 28 (for early dropouts the last 7 days staying in the study)

  27. Percentage of Patients With Relief of Daytime Heartburn After 1 Week of Treatment

    To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on heartburn, as measured by: Relief of daytime heartburn after 2 weeks of treatment. Results based on MITT population with available data for this outcome measure. Relief of daytime, nighttime, and 24-hour heartburn was defined as a daily diary response of "none" on at least 6 of 7 days, allowing for 1 "mild" response.'

    Time frame: 1 week

  28. Percentage of Patients With Relief of Daytime Heartburn After 2 Weeks of Treatment

    To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on heartburn, as measured by: Relief of daytime heartburn after 2 weeks of treatment. Relief of daytime, nighttime, and 24-hour heartburn was defined as a daily diary response of "none" on at least 6 of 7 days, allowing for 1 "mild" response.'

    Time frame: 2 weeks

  29. Percentage of Patients With Relief of Daytime Heartburn After 4 Weeks of Treatment

    To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on heartburn, as measured by: Relief of daytime heartburn after 4 weeks of treatment. Relief of daytime, nighttime, and 24-hour heartburn was defined as a daily diary response of "none" on at least 6 of 7 days, allowing for 1 "mild" response.'

    Time frame: 4 weeks

  30. Percentage of Patients With Relief of Daytime Heartburn on the Patient's Last 7 Days in the Study

    To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on heartburn, as measured by: Relief of daytime heartburn on the patient's last 7 days in the study. Relief of daytime, nighttime, and 24-hour heartburn was defined as a daily diary response of "none" on at least 6 of 7 days, allowing for 1 "mild" response.'

    Time frame: Days 21- 28 (for early dropouts the last 7 days staying in the study)

  31. Percentage of Patients With Relief of Nighttime Heartburn After 1 Week of Treatment.

    To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on heartburn, as measured by: Relief of nighttime heartburn after 1 week of treatment. Relief of daytime, nighttime, and 24-hour heartburn was defined as a daily diary response of "none" on at least 6 of 7 days, allowing for 1 "mild" response.

    Time frame: 1 week

  32. Percentage of Patients With Relief of Nighttime Heartburn After 2 Weeks of Treatment

    To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on heartburn, as measured by: Relief of nighttime heartburn after 2 weeks of treatment. Relief of daytime, nighttime, and 24-hour heartburn was defined as a daily diary response of "none" on at least 6 of 7 days, allowing for 1 "mild" response.

    Time frame: 2 weeks

  33. Percentage of Patients With Relief of Nighttime Heartburn After 4 Weeks of Treatment

    To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on heartburn, as measured by: Relief of nighttime heartburn after 4 weeks of treatment. Relief of daytime, nighttime, and 24-hour heartburn was defined as a daily diary response of "none" on at least 6 of 7 days, allowing for 1 "mild" response.

    Time frame: 4 weeks

  34. Percentage of Patients With Relief of Nighttime Heartburn on the Patient's Last 7 Days in the Study

    To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on heartburn, as measured by: Relief of nighttime heartburn on the patient's last 7 days in the study. Relief of daytime, nighttime, and 24-hour heartburn was defined as a daily diary response of "none" on at least 6 of 7 days, allowing for 1 "mild" response.

    Time frame: Days 21- 28 (for early dropouts the last 7 days staying in the study)

  35. Percentage of Patients With Relief of 24-hour Heartburn After 1 Week of Treatment

    To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on heartburn, as measured by: Relief of 24-hour heartburn after 1 week of treatment. Relief of daytime, nighttime, and 24-hour heartburn was defined as a daily diary response of "none" on at least 6 of 7 days, allowing for 1 "mild" response.

    Time frame: 1 week

  36. Percentage of Patients With Relief of 24-hour Heartburn After 2 Weeks of Treatment

    To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on heartburn, as measured by: Relief of 24-hour heartburn after 2 weeks of treatment. Relief of daytime, nighttime, and 24-hour heartburn was defined as a daily diary response of "none" on at least 6 of 7 days, allowing for 1 "mild" response.

    Time frame: 2 weeks

  37. Percentage of Patients With Relief of 24-hour Heartburn After 4 Weeks of Treatment

    To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on heartburn, as measured by: Relief of 24-hour heartburn after 4 weeks of treatment. Relief of daytime, nighttime, and 24-hour heartburn was defined as a daily diary response of "none" on at least 6 of 7 days, allowing for 1 "mild" response.

    Time frame: 4 weeks

  38. Percentage of Patients With Relief of 24-hour Heartburn on the Patient's Last 7 Days in the Study

    To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on heartburn, as measured by: Relief of 24-hour heartburn on the patient's last 7 days in the study. Relief of daytime, nighttime, and 24-hour heartburn was defined as a daily diary response of "none" on at least 6 of 7 days, allowing for 1 "mild" response.

    Time frame: Days 21- 28 (for early dropouts the last 7 days staying in the study)

  39. Percentage of Patients With Nighttime Heartburn Symptom Improvement From Baseline During the Last 7 Days in the Study

    Number and percentage of patients with nighttime heartburn symptom improvement based on weekly symptom scores at Baseline compared to the last week of study drug treatment. Symptom improvement was defined as any decrease in weekly symptom score from Baseline until the last 7 days in the study.

    Time frame: Days 21- 28 (for early dropouts the last 7 days staying in the study)

  40. Percentage of Participants With Daytime Heartburn Symptom Improvement From Baseline During the Last 7 Days in the Study

    Number of patients with daytime heartburn symptom improvement based on weekly symptom scores at Baseline compared to the last week of study drug treatment. Symptom improvement was defined as any decrease in weekly symptom score from Baseline until the last 7 days in the study.

    Time frame: Days 21-28 (for early dropouts the last 7 days staying in the study)

  41. Percentage of Patients With 24-hour Heartburn Symptom Improvement From Baseline During the Last 7 Days in the Study.

    Number of patients with 24-hour heartburn symptom improvement based on weekly symptom scores at Baseline compared to the last week of study drug treatment. Symptom improvement was defined as any decrease in weekly symptom score from Baseline until the last 7 days in the study.

    Time frame: Days 21- 28 (for early dropouts the last 7 days staying in the study)

  42. Equivalent Number of Hours Lost Because of Sleep Disturbances Due to Gastroesophageal Reflux Disease (GERD) Symptoms (Average)

    Time frame: 4 weeks

  43. Change From Baseline in Percent of Work Impairment Because of Sleep Disturbances Due to Gastroesophageal Reflux Disease (GERD) Symptoms (Average)

    Degree of sleep disturbance affecting work productivity. 100% is considered to be the worst outcome where there is no ability to work. 0% is considered to be the best outcome, no impairment.

    Time frame: Baseline and 4 weeks

  44. Change From Baseline in Percent Overall Work Impairment Due to Sleep Disturbance (Average)

    Equivalent number of work hours missed was derived from questions 2, 4 and 5 of the Work Productivity and Activity Impairment Questionnaire: Sleep Disturbance-GERD (Gastroesophageal Reflux Disease) and summed up with the percent work impairment during the remaining hours that were actually worked.

    Time frame: Baseline and 4 weeks

  45. Change From Baseline in Percent Activity Impairment Due to Sleep Disturbances (Average)

    To assess the impact of treatment as measured by: Change in global Pittsburgh Sleep Quality Index (PSQI) scores from baseline to week 4. Scale details -'Scoring ranged from 0, "no difficulty" to 3, "severe difficulty." Items were grouped into 7 component scores. The 7 components were then summed to yield a global PSQI score. Global scores \>5 were considered to meet the criteria of sleep disturbance.

    Time frame: Baseline and 4 weeks

  46. Monetary Value of Work Hours Saved

    The monetary value of the work hours saved was derived from questions 2,4, and 5 of the WPAI and a standard hourly compensation rate reported by the US Bureau of Labor Statistics (US$28.48 as of June 2008).

    Time frame: Week 4

07

Results

Posted Mar 2, 2015

Participant flow

The baseline figures shown will be for the modified intention to treat population. One patient in each treatment group did not receive study drug; therefore, the safety population has one less patient in each treatment than does the randomized study population.

Participant flow — Overall Study
MilestoneNexium 20 mgPlacebo
Started143133
Met criteria for mitt population137125
Completed138124
Not completed59
Withdrew: Adverse event10
Withdrew: Lost to follow-up06
Withdrew: Lack of efficacy02
Withdrew: Withdrawal by subject30
Withdrew: Incorrect enrollment and other01
Withdrew: New medication after randomization10

Outcome measures

PrimaryPercentage of Patients With Relief of Nighttime Heartburn During the Last 7 Days of the Study.

Relief of nighttime heartburn on patient's last 7 days in the study. Relief was defined as a daily diary card response of "none" or 0, on at least 6 of 7 days, allowing for one "mild" or 1 response. Diary card scale (none, mild, moderate, severe).

Time frame:
Days 21- 28 (for early dropouts the last 7 days staying in the study)
Reported as:
Number · Percentage of participants
Percentage of Patients With Relief of Nighttime Heartburn During the Last 7 Days of the Study.
Percentage of participantsNexium 20 mgPlacebo
Percentage of Patients With Relief of Nighttime Heartburn During the Last 7 Days of the Study.34.310.4
SecondaryChange in Mean (Average) Pittsburgh Sleep Quality Index (PSQI) Scores From Baseline

To assess the impact of treatment as measured by: Change in global Pittsburgh Sleep Quality Index (PSQI) scores from baseline to week 4. Scale details -'Scoring ranged from 0, "no difficulty" to 3, "severe difficulty." Items were grouped into 7 component scores. The 7 components were then summed to yield a global PSQI score. Global scores \>5 were considered to meet the criteria of sleep disturbance.

Time frame:
Baseline and 4 weeks
Reported as:
Least squares mean · Scores on a scale
Change in Mean (Average) Pittsburgh Sleep Quality Index (PSQI) Scores From Baseline
Scores on a scaleNexium 20 mgPlacebo
Change in Mean (Average) Pittsburgh Sleep Quality Index (PSQI) Scores From Baseline-2.93 ± 0.34-1.80 ± 0.34
SecondaryAchievement of Developer-defined Good Sleep

To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on sleep disturbances associated with Gastroesophageal reflux disease (GERD), as measured by achievement of (yes/no) developer-defined good sleep (global Pittsburgh Sleep Quality Index - PSQI score ≤5) at Week 4.

Time frame:
4 weeks
Reported as:
Number · Participants
Achievement of Developer-defined Good Sleep
ParticipantsNexium 20 mgPlacebo
Achievement of Developer-defined Good Sleep1924
SecondaryNumber of Patients With Complete Resolution of Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD) After 1 Week of Treatment.

The assessment was based on patients registrations of the answers "Yes" or "No" to the question: "Did you have trouble sleeping last night due to your heartburn or other symptoms of Gastroesophageal Reflux Disease (GERD)?". Complete resolution of GERD-related sleep disturbances was defined as a daily diary response of "No" on 7 consecutive days.

Time frame:
1 week
Reported as:
Number · Participants
Number of Patients With Complete Resolution of Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD) After 1 Week of Treatment.
ParticipantsNexium 20 mgPlacebo
Number of Patients With Complete Resolution of Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD) After 1 Week of Treatment.4423
SecondaryNumber of Patients With Complete Resolution of Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD) After 2 Weeks of Treatment.

The assessment was based on patients registrations of the answers "Yes" or "No" to the question: "Did you have trouble sleeping last night due to your heartburn or other symptoms of Gastroesophageal Reflux Disease (GERD)?". Complete resolution of GERD-related sleep disturbances was defined as a daily diary response of "No" on 14 consecutive days.

Time frame:
2 weeks
Reported as:
Number · Participants
Number of Patients With Complete Resolution of Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD) After 2 Weeks of Treatment.
ParticipantsNexium 20 mgPlacebo
Number of Patients With Complete Resolution of Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD) After 2 Weeks of Treatment.5420
SecondaryNumber of Patients With Complete Resolution of Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD) After 4 Weeks of Treatment.

The assessment was based on patients registrations of the answers "Yes" or "No" to the question: "Did you have trouble sleeping last night due to your heartburn or other symptoms of GERD?". Complete resolution of Gastroesophageal Reflux Disease (GERD)-related sleep disturbances was defined as a daily diary response of "No" on 7 consecutive days during 4 weeks of treatment.

Time frame:
4 weeks
Reported as:
Number · Participants
Number of Patients With Complete Resolution of Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD) After 4 Weeks of Treatment.
ParticipantsNexium 20 mgPlacebo
Number of Patients With Complete Resolution of Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD) After 4 Weeks of Treatment.2914
SecondaryNumber of Patients With Complete Resolution of Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD) on the Patient's Last 7 Days in the Study.

To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on sleep disturbances associated with Gastroesophageal Reflux Disease (GERD), as measured by: Complete resolution of sleep disturbances on the patient's last 7 days in the study.

Time frame:
Days 21- 28 (for early dropouts the last 7 days staying in the study)
Reported as:
Number · Participants
Number of Patients With Complete Resolution of Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD) on the Patient's Last 7 Days in the Study.
ParticipantsNexium 20 mgPlacebo
Number of Patients With Complete Resolution of Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD) on the Patient's Last 7 Days in the Study.6627
SecondaryNumber of Patients With Relief of Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD) After 1 Week of Treatment

The assessment was based on patients registrations of the answers "Yes" or "No" to the question: "Did you have trouble sleeping last night due to your heartburn or other symptoms of Gastroesophageal Reflux Disease (GERD)?". Relief of sleep disturbances associated with GERD was defined as a daily diary response of "Yes" on not more than 2 of 7 consecutive days.

Time frame:
1 week
Reported as:
Number · Participants
Number of Patients With Relief of Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD) After 1 Week of Treatment
ParticipantsNexium 20 mgPlacebo
Number of Patients With Relief of Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD) After 1 Week of Treatment7953
SecondaryNumber of Patients With Relief of Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD) After 2 Weeks of Treatment

The assessment was based on patients registrations of the answers "Yes" or "No" to the question: "Did you have trouble sleeping last night due to your heartburn or other symptoms of Gastroesophageal Reflux Disease (GERD)?". Relief of sleep disturbances associated with GERD was defined as a daily diary response of "Yes" on not more than 2 of 7 consecutive days.

Time frame:
2 weeks
Reported as:
Number · Participants
Number of Patients With Relief of Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD) After 2 Weeks of Treatment
ParticipantsNexium 20 mgPlacebo
Number of Patients With Relief of Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD) After 2 Weeks of Treatment9054
SecondaryNumber of Patients With Relief of Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD) After 4 Weeks of Treatment

The assessment was based on patients registrations of the answers "Yes" or "No" to the question: "Did you have trouble sleeping last night due to your heartburn or other symptoms of Gastroesophageal Reflux Disease (GERD)?". Relief of sleep disturbances associated with GERD was defined as a daily diary response of "Yes" on not more than 2 of 7 consecutive days.

Time frame:
4 weeks
Reported as:
Number · Participants
Number of Patients With Relief of Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD) After 4 Weeks of Treatment
ParticipantsNexium 20 mgPlacebo
Number of Patients With Relief of Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD) After 4 Weeks of Treatment7445
SecondaryPercentage of Patients With Relief of Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD) on the Patient's Last 7 Days in the Study.

The assessment was based on patients registrations of the answers "Yes" or "No" to the question: "Did you have trouble sleeping last night due to your heartburn or other symptoms of Gastroesophageal Reflux Disease (GERD)?". Relief of sleep disturbances associated with GERD was defined as a daily diary response of "Yes" on not more than 2 of 7 consecutive days.

Time frame:
Days 21- 28 (for early dropouts the last 7 days staying in the study)
Reported as:
Number · Percentage of Participants
Percentage of Patients With Relief of Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD) on the Patient's Last 7 Days in the Study.
Percentage of ParticipantsNexium 20 mgPlacebo
Percentage of Patients With Relief of Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD) on the Patient's Last 7 Days in the Study.71.555.2
SecondaryPercentage of Days Without Gastroesophageal Reflux Disease (GERD)-Related Sleep Disturbances During the 4 Week Period

To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on sleep disturbances associated with Gastroesophageal Reflux Disease (GERD)as measured by: Percent of days without sleep disturbances after 4 weeks of treatment. Each morning of the study, patients registered their answer "Yes" or "No" to the question, "Did you have trouble sleeping last night due to your heartburn or other symptoms of GERD?" in the diary card.'

Time frame:
4 weeks
Reported as:
Mean · Percentage of days
Percentage of Days Without Gastroesophageal Reflux Disease (GERD)-Related Sleep Disturbances During the 4 Week Period
Percentage of daysNexium 20 mgPlacebo
Percentage of Days Without Gastroesophageal Reflux Disease (GERD)-Related Sleep Disturbances During the 4 Week Period73.0 ± 29.759.3 ± 29.9
SecondaryNumber of Days to First Relief of Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD) During the 4 Week Treatment Period

The assessment was based on patients registrations of the answers "Yes" or "No" to the question: "Did you have trouble sleeping last night due to your heartburn or other symptoms of Gastroesophageal Reflux Disease (GERD)?". Relief of sleep disturbances associated with GERD was defined as a daily diary response of "Yes" on not more than 2 of 7 consecutive days, and 'days to first relief' was defined as the first day of the 7 days that reached relief of sleep disturbance.

Time frame:
4 weeks
Reported as:
Median · Days
Number of Days to First Relief of Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD) During the 4 Week Treatment Period
DaysNexium 20 mgPlacebo
Number of Days to First Relief of Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD) During the 4 Week Treatment Period1 (1 to 21)3 (1 to 21)
SecondaryNumber of Days to Resolution of Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD) During the 4 Week Treatment Period

The assessment was based on patients registrations of the answers "Yes" or "No" to the question: "Did you have trouble sleeping last night due to your heartburn or other symptoms of Gastroesophageal Reflux Disease (GERD)?". Relief of sleep disturbances associated with GERD was defined as a daily diary response of "Yes" on not more than 2 of 7 consecutive days.

Time frame:
4 weeks
Reported as:
Median · Days
Number of Days to Resolution of Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD) During the 4 Week Treatment Period
DaysNexium 20 mgPlacebo
Number of Days to Resolution of Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD) During the 4 Week Treatment Period1 (1 to 14)2 (1 to 21)
SecondaryNumber of Days to First Complete Resolution of Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD) During the 4 Week Treatment Period

To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on sleep disturbances associated with Gastroesophageal Reflux Disease (GERD), as measured by: Days to complete resolution of sleep disturbance. Days to complete resolution of sleep disturbances associated with GERD was defined as the number of days until the first day of the first 7-consecutive-day period during which the patient's daily diary response was "No" (did not have trouble sleeping due to GERD symptoms).'

Time frame:
4 weeks
Reported as:
Median · Days
Number of Days to First Complete Resolution of Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD) During the 4 Week Treatment Period
DaysNexium 20 mgPlacebo
Number of Days to First Complete Resolution of Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD) During the 4 Week Treatment Period9 (1 to 21)21 (1 to 21)
SecondaryPercentage of Patients With Complete Resolution of Daytime Heartburn After 1 Week of Treatment

To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on heartburn, as measured by: Complete resolution of daytime heartburn after 1 week of treatment. Results based on MITT population with available data for this outcome measure. Complete resolution of daytime, nighttime, and 24-hour heartburn was defined as a daily diary response of "None" on 7 consecutive days.

Time frame:
1 week
Reported as:
Number · Percentage of participants
Percentage of Patients With Complete Resolution of Daytime Heartburn After 1 Week of Treatment
Percentage of participantsNexium 20 mgPlacebo
Percentage of Patients With Complete Resolution of Daytime Heartburn After 1 Week of Treatment224
SecondaryPercentage of Patients With Complete Resolution of Daytime Heartburn After 2 Weeks of Treatment

To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on heartburn, as measured by: Complete resolution of daytime heartburn after 2 weeks of treatment. Complete resolution of daytime, nighttime, and 24-hour heartburn was defined as a daily diary response of "None" on 7 consecutive days.

Time frame:
2 weeks
Reported as:
Number · Percentage of participants
Percentage of Patients With Complete Resolution of Daytime Heartburn After 2 Weeks of Treatment
Percentage of participantsNexium 20 mgPlacebo
Percentage of Patients With Complete Resolution of Daytime Heartburn After 2 Weeks of Treatment3711
SecondaryPercentage of Patients With Complete Resolution of Daytime Heartburn After 4 Weeks of Treatment

To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on heartburn, as measured by: Complete resolution of daytime heartburn after 4 weeks of treatment. Complete resolution of daytime, nighttime, and 24-hour heartburn was defined as a daily diary response of "None" on 7 consecutive days.

Time frame:
4 weeks
Reported as:
Number · Percentage of participants
Percentage of Patients With Complete Resolution of Daytime Heartburn After 4 Weeks of Treatment
Percentage of participantsNexium 20 mgPlacebo
Percentage of Patients With Complete Resolution of Daytime Heartburn After 4 Weeks of Treatment357
SecondaryPercentage of Patients With Complete Resolution of Daytime Heartburn on the Patient's Last 7 Days in the Study

To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on heartburn, as measured by: Complete resolution of daytime heartburn on the patient's last 7 days in the study. Complete resolution of daytime, nighttime, and 24-hour heartburn was defined as a daily diary response of "None" on 7 consecutive days.

Time frame:
Days 21- 28 (for early dropouts the last 7 days staying in the study)
Reported as:
Number · Percentage of participants
Percentage of Patients With Complete Resolution of Daytime Heartburn on the Patient's Last 7 Days in the Study
Percentage of participantsNexium 20 mgPlacebo
Percentage of Patients With Complete Resolution of Daytime Heartburn on the Patient's Last 7 Days in the Study459
SecondaryPercentage of Patients With Complete Resolution of Nighttime Heartburn After 1 Week of Treatment.

To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on heartburn, as measured by: Complete resolution of nighttime heartburn after 1 week of treatment. Complete resolution of daytime, nighttime, and 24-hour heartburn was defined as a daily diary response of "None" on 7 consecutive days.

Time frame:
1 week
Reported as:
Number · Percentage of participants
Percentage of Patients With Complete Resolution of Nighttime Heartburn After 1 Week of Treatment.
Percentage of participantsNexium 20 mgPlacebo
Percentage of Patients With Complete Resolution of Nighttime Heartburn After 1 Week of Treatment.234
SecondaryPercentage of Patients With Complete Resolution of Nighttime Heartburn After 2 Weeks of Treatment

To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on heartburn, as measured by: Complete resolution of nighttime heartburn after 2 weeks of treatment. Complete resolution of daytime, nighttime, and 24-hour heartburn was defined as a daily diary response of "None" on 7 consecutive days.

Time frame:
2 weeks
Reported as:
Number · Percentage of participants
Percentage of Patients With Complete Resolution of Nighttime Heartburn After 2 Weeks of Treatment
Percentage of participantsNexium 20 mgPlacebo
Percentage of Patients With Complete Resolution of Nighttime Heartburn After 2 Weeks of Treatment366
SecondaryPercentage of Patients With Complete Resolution of Nighttime Heartburn After 4 Weeks of Treatment

To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on heartburn, as measured by: Complete resolution of nighttime heartburn after 4 weeks of treatment. Complete resolution of daytime, nighttime, and 24-hour heartburn was defined as a daily diary response of "None" on 7 consecutive days.

Time frame:
4 weeks
Reported as:
Number · Percentage of participants
Percentage of Patients With Complete Resolution of Nighttime Heartburn After 4 Weeks of Treatment
Percentage of participantsNexium 20 mgPlacebo
Percentage of Patients With Complete Resolution of Nighttime Heartburn After 4 Weeks of Treatment256
SecondaryPercentage of Patients With Complete Resolution of Nighttime Heartburn on the Patient's Last 7 Days in the Study.

To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on heartburn, as measured by: Complete resolution of nighttime heartburn on the patient's last 7 days in the study. Complete resolution of daytime, nighttime, and 24-hour heartburn was defined as a daily diary response of "None" on 7 consecutive days.

Time frame:
Days 21- 28 (for early dropouts the last 7 days staying in the study)
Reported as:
Number · Percentage of participants
Percentage of Patients With Complete Resolution of Nighttime Heartburn on the Patient's Last 7 Days in the Study.
Percentage of participantsNexium 20 mgPlacebo
Percentage of Patients With Complete Resolution of Nighttime Heartburn on the Patient's Last 7 Days in the Study.428
SecondaryPercentage of Patients With Complete Resolution of 24-hour Heartburn After 1 Week of Treatment

To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on heartburn, as measured by: Complete resolution of 24-hour heartburn after 1 week of treatment. Complete resolution of daytime, nighttime, and 24-hour heartburn was defined as a daily diary response of "None" on 7 consecutive days.

Time frame:
1 week
Reported as:
Number · Percentage of participants
Percentage of Patients With Complete Resolution of 24-hour Heartburn After 1 Week of Treatment
Percentage of participantsNexium 20 mgPlacebo
Percentage of Patients With Complete Resolution of 24-hour Heartburn After 1 Week of Treatment163
SecondaryPercentage of Patients With Complete Resolution of 24-hour Heartburn After 2 Weeks of Treatment

To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on heartburn, as measured by: Complete resolution of 24-hour heartburn after 2 weeks of treatment. Complete resolution of daytime, nighttime, and 24-hour heartburn was defined as a daily diary response of "None" on 7 consecutive days.

Time frame:
2 weeks
Reported as:
Number · Percentage of participants
Percentage of Patients With Complete Resolution of 24-hour Heartburn After 2 Weeks of Treatment
Percentage of participantsNexium 20 mgPlacebo
Percentage of Patients With Complete Resolution of 24-hour Heartburn After 2 Weeks of Treatment304
SecondaryPercentage of Patients With Complete Resolution of 24-hour Heartburn After 4 Weeks of Treatment

To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on heartburn, as measured by: Complete resolution of 24-hour heartburn after 4 weeks of treatment. Complete resolution of daytime, nighttime, and 24-hour heartburn was defined as a daily diary response of "None" on 7 consecutive days.

Time frame:
4 weeks
Reported as:
Number · Percentage of participants
Percentage of Patients With Complete Resolution of 24-hour Heartburn After 4 Weeks of Treatment
Percentage of participantsNexium 20 mgPlacebo
Percentage of Patients With Complete Resolution of 24-hour Heartburn After 4 Weeks of Treatment304
SecondaryPercentage of Patients With Complete Resolution of 24-hour Heartburn on the Patient's Last 7 Days in the Study

To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on heartburn, as measured by: Complete resolution of 24-hour heartburn on the patient's last 7 days in the study. Complete resolution of daytime, nighttime, and 24-hour heartburn was defined as a daily diary response of "None" on 7 consecutive days.

Time frame:
Days 21- 28 (for early dropouts the last 7 days staying in the study)
Reported as:
Number · Percentage of participants
Percentage of Patients With Complete Resolution of 24-hour Heartburn on the Patient's Last 7 Days in the Study
Percentage of participantsNexium 20 mgPlacebo
Percentage of Patients With Complete Resolution of 24-hour Heartburn on the Patient's Last 7 Days in the Study375
SecondaryPercentage of Patients With Relief of Daytime Heartburn After 1 Week of Treatment

To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on heartburn, as measured by: Relief of daytime heartburn after 2 weeks of treatment. Results based on MITT population with available data for this outcome measure. Relief of daytime, nighttime, and 24-hour heartburn was defined as a daily diary response of "none" on at least 6 of 7 days, allowing for 1 "mild" response.'

Time frame:
1 week
Reported as:
Number · Percentage of participants
Percentage of Patients With Relief of Daytime Heartburn After 1 Week of Treatment
Percentage of participantsNexium 20 mgPlacebo
Percentage of Patients With Relief of Daytime Heartburn After 1 Week of Treatment3413
SecondaryPercentage of Patients With Relief of Daytime Heartburn After 2 Weeks of Treatment

To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on heartburn, as measured by: Relief of daytime heartburn after 2 weeks of treatment. Relief of daytime, nighttime, and 24-hour heartburn was defined as a daily diary response of "none" on at least 6 of 7 days, allowing for 1 "mild" response.'

Time frame:
2 weeks
Reported as:
Number · Percentage of participants
Percentage of Patients With Relief of Daytime Heartburn After 2 Weeks of Treatment
Percentage of participantsNexium 20 mgPlacebo
Percentage of Patients With Relief of Daytime Heartburn After 2 Weeks of Treatment4814
SecondaryPercentage of Patients With Relief of Daytime Heartburn After 4 Weeks of Treatment

To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on heartburn, as measured by: Relief of daytime heartburn after 4 weeks of treatment. Relief of daytime, nighttime, and 24-hour heartburn was defined as a daily diary response of "none" on at least 6 of 7 days, allowing for 1 "mild" response.'

Time frame:
4 weeks
Reported as:
Number · Percentage of participants
Percentage of Patients With Relief of Daytime Heartburn After 4 Weeks of Treatment
Percentage of participantsNexium 20 mgPlacebo
Percentage of Patients With Relief of Daytime Heartburn After 4 Weeks of Treatment409
SecondaryPercentage of Patients With Relief of Daytime Heartburn on the Patient's Last 7 Days in the Study

To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on heartburn, as measured by: Relief of daytime heartburn on the patient's last 7 days in the study. Relief of daytime, nighttime, and 24-hour heartburn was defined as a daily diary response of "none" on at least 6 of 7 days, allowing for 1 "mild" response.'

Time frame:
Days 21- 28 (for early dropouts the last 7 days staying in the study)
Reported as:
Number · Percentage of participants
Percentage of Patients With Relief of Daytime Heartburn on the Patient's Last 7 Days in the Study
Percentage of participantsNexium 20 mgPlacebo
Percentage of Patients With Relief of Daytime Heartburn on the Patient's Last 7 Days in the Study5514
SecondaryPercentage of Patients With Relief of Nighttime Heartburn After 1 Week of Treatment.

To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on heartburn, as measured by: Relief of nighttime heartburn after 1 week of treatment. Relief of daytime, nighttime, and 24-hour heartburn was defined as a daily diary response of "none" on at least 6 of 7 days, allowing for 1 "mild" response.

Time frame:
1 week
Reported as:
Number · Percentage of participants
Percentage of Patients With Relief of Nighttime Heartburn After 1 Week of Treatment.
Percentage of participantsNexium 20 mgPlacebo
Percentage of Patients With Relief of Nighttime Heartburn After 1 Week of Treatment.289
SecondaryPercentage of Patients With Relief of Nighttime Heartburn After 2 Weeks of Treatment

To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on heartburn, as measured by: Relief of nighttime heartburn after 2 weeks of treatment. Relief of daytime, nighttime, and 24-hour heartburn was defined as a daily diary response of "none" on at least 6 of 7 days, allowing for 1 "mild" response.

Time frame:
2 weeks
Reported as:
Number · Percentage of participants
Percentage of Patients With Relief of Nighttime Heartburn After 2 Weeks of Treatment
Percentage of participantsNexium 20 mgPlacebo
Percentage of Patients With Relief of Nighttime Heartburn After 2 Weeks of Treatment407
SecondaryPercentage of Patients With Relief of Nighttime Heartburn After 4 Weeks of Treatment

To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on heartburn, as measured by: Relief of nighttime heartburn after 4 weeks of treatment. Relief of daytime, nighttime, and 24-hour heartburn was defined as a daily diary response of "none" on at least 6 of 7 days, allowing for 1 "mild" response.

Time frame:
4 weeks
Reported as:
Number · Percentage of participants
Percentage of Patients With Relief of Nighttime Heartburn After 4 Weeks of Treatment
Percentage of participantsNexium 20 mgPlacebo
Percentage of Patients With Relief of Nighttime Heartburn After 4 Weeks of Treatment266
SecondaryPercentage of Patients With Relief of Nighttime Heartburn on the Patient's Last 7 Days in the Study

To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on heartburn, as measured by: Relief of nighttime heartburn on the patient's last 7 days in the study. Relief of daytime, nighttime, and 24-hour heartburn was defined as a daily diary response of "none" on at least 6 of 7 days, allowing for 1 "mild" response.

Time frame:
Days 21- 28 (for early dropouts the last 7 days staying in the study)
Reported as:
Number · Percentage of participants
Percentage of Patients With Relief of Nighttime Heartburn on the Patient's Last 7 Days in the Study
Percentage of participantsNexium 20 mgPlacebo
Percentage of Patients With Relief of Nighttime Heartburn on the Patient's Last 7 Days in the Study4713
SecondaryPercentage of Patients With Relief of 24-hour Heartburn After 1 Week of Treatment

To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on heartburn, as measured by: Relief of 24-hour heartburn after 1 week of treatment. Relief of daytime, nighttime, and 24-hour heartburn was defined as a daily diary response of "none" on at least 6 of 7 days, allowing for 1 "mild" response.

Time frame:
1 week
Reported as:
Number · Percentage of participants
Percentage of Patients With Relief of 24-hour Heartburn After 1 Week of Treatment
Percentage of participantsNexium 20 mgPlacebo
Percentage of Patients With Relief of 24-hour Heartburn After 1 Week of Treatment275
SecondaryPercentage of Patients With Relief of 24-hour Heartburn After 2 Weeks of Treatment

To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on heartburn, as measured by: Relief of 24-hour heartburn after 2 weeks of treatment. Relief of daytime, nighttime, and 24-hour heartburn was defined as a daily diary response of "none" on at least 6 of 7 days, allowing for 1 "mild" response.

Time frame:
2 weeks
Reported as:
Number · Percentage of participants
Percentage of Patients With Relief of 24-hour Heartburn After 2 Weeks of Treatment
Percentage of participantsNexium 20 mgPlacebo
Percentage of Patients With Relief of 24-hour Heartburn After 2 Weeks of Treatment365
SecondaryPercentage of Patients With Relief of 24-hour Heartburn After 4 Weeks of Treatment

To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on heartburn, as measured by: Relief of 24-hour heartburn after 4 weeks of treatment. Relief of daytime, nighttime, and 24-hour heartburn was defined as a daily diary response of "none" on at least 6 of 7 days, allowing for 1 "mild" response.

Time frame:
4 weeks
Reported as:
Number · Percentage of participants
Percentage of Patients With Relief of 24-hour Heartburn After 4 Weeks of Treatment
Percentage of participantsNexium 20 mgPlacebo
Percentage of Patients With Relief of 24-hour Heartburn After 4 Weeks of Treatment335
SecondaryPercentage of Patients With Relief of 24-hour Heartburn on the Patient's Last 7 Days in the Study

To assess the impact of treatment with Esomeprazole 20 (E20) versus placebo on heartburn, as measured by: Relief of 24-hour heartburn on the patient's last 7 days in the study. Relief of daytime, nighttime, and 24-hour heartburn was defined as a daily diary response of "none" on at least 6 of 7 days, allowing for 1 "mild" response.

Time frame:
Days 21- 28 (for early dropouts the last 7 days staying in the study)
Reported as:
Number · Percentage of participants
Percentage of Patients With Relief of 24-hour Heartburn on the Patient's Last 7 Days in the Study
Percentage of participantsNexium 20 mgPlacebo
Percentage of Patients With Relief of 24-hour Heartburn on the Patient's Last 7 Days in the Study459
SecondaryPercentage of Patients With Nighttime Heartburn Symptom Improvement From Baseline During the Last 7 Days in the Study

Number and percentage of patients with nighttime heartburn symptom improvement based on weekly symptom scores at Baseline compared to the last week of study drug treatment. Symptom improvement was defined as any decrease in weekly symptom score from Baseline until the last 7 days in the study.

Time frame:
Days 21- 28 (for early dropouts the last 7 days staying in the study)
Reported as:
Number · Percentage of participants
Percentage of Patients With Nighttime Heartburn Symptom Improvement From Baseline During the Last 7 Days in the Study
Percentage of participantsNexium 20 mgPlacebo
Percentage of Patients With Nighttime Heartburn Symptom Improvement From Baseline During the Last 7 Days in the Study89.883.2
SecondaryPercentage of Participants With Daytime Heartburn Symptom Improvement From Baseline During the Last 7 Days in the Study

Number of patients with daytime heartburn symptom improvement based on weekly symptom scores at Baseline compared to the last week of study drug treatment. Symptom improvement was defined as any decrease in weekly symptom score from Baseline until the last 7 days in the study.

Time frame:
Days 21-28 (for early dropouts the last 7 days staying in the study)
Reported as:
Number · Percentage of participants
Percentage of Participants With Daytime Heartburn Symptom Improvement From Baseline During the Last 7 Days in the Study
Percentage of participantsNexium 20 mgPlacebo
Percentage of Participants With Daytime Heartburn Symptom Improvement From Baseline During the Last 7 Days in the Study86.176
SecondaryPercentage of Patients With 24-hour Heartburn Symptom Improvement From Baseline During the Last 7 Days in the Study.

Number of patients with 24-hour heartburn symptom improvement based on weekly symptom scores at Baseline compared to the last week of study drug treatment. Symptom improvement was defined as any decrease in weekly symptom score from Baseline until the last 7 days in the study.

Time frame:
Days 21- 28 (for early dropouts the last 7 days staying in the study)
Reported as:
Number · Percentage of participants
Percentage of Patients With 24-hour Heartburn Symptom Improvement From Baseline During the Last 7 Days in the Study.
Percentage of participantsNexium 20 mgPlacebo
Percentage of Patients With 24-hour Heartburn Symptom Improvement From Baseline During the Last 7 Days in the Study.89.880
SecondaryEquivalent Number of Hours Lost Because of Sleep Disturbances Due to Gastroesophageal Reflux Disease (GERD) Symptoms (Average)
Time frame:
4 weeks
Reported as:
Mean · Work hours
Equivalent Number of Hours Lost Because of Sleep Disturbances Due to Gastroesophageal Reflux Disease (GERD) Symptoms (Average)
Work hoursNexium 20 mgPlacebo
Equivalent Number of Hours Lost Because of Sleep Disturbances Due to Gastroesophageal Reflux Disease (GERD) Symptoms (Average)8.9 ± 11.15.2 ± 11.7
SecondaryChange From Baseline in Percent of Work Impairment Because of Sleep Disturbances Due to Gastroesophageal Reflux Disease (GERD) Symptoms (Average)

Degree of sleep disturbance affecting work productivity. 100% is considered to be the worst outcome where there is no ability to work. 0% is considered to be the best outcome, no impairment.

Time frame:
Baseline and 4 weeks
Reported as:
Mean · Percentage
Change From Baseline in Percent of Work Impairment Because of Sleep Disturbances Due to Gastroesophageal Reflux Disease (GERD) Symptoms (Average)
PercentageNexium 20 mgPlacebo
Change From Baseline in Percent of Work Impairment Because of Sleep Disturbances Due to Gastroesophageal Reflux Disease (GERD) Symptoms (Average)-25.3 ± 28.7-14 ± 27.4
SecondaryChange From Baseline in Percent Overall Work Impairment Due to Sleep Disturbance (Average)

Equivalent number of work hours missed was derived from questions 2, 4 and 5 of the Work Productivity and Activity Impairment Questionnaire: Sleep Disturbance-GERD (Gastroesophageal Reflux Disease) and summed up with the percent work impairment during the remaining hours that were actually worked.

Time frame:
Baseline and 4 weeks
Reported as:
Mean · Percentage
Change From Baseline in Percent Overall Work Impairment Due to Sleep Disturbance (Average)
PercentageNexium 20 mgPlacebo
Change From Baseline in Percent Overall Work Impairment Due to Sleep Disturbance (Average)-24.8 ± 29.5-14.9 ± 25.9
SecondaryChange From Baseline in Percent Activity Impairment Due to Sleep Disturbances (Average)

To assess the impact of treatment as measured by: Change in global Pittsburgh Sleep Quality Index (PSQI) scores from baseline to week 4. Scale details -'Scoring ranged from 0, "no difficulty" to 3, "severe difficulty." Items were grouped into 7 component scores. The 7 components were then summed to yield a global PSQI score. Global scores \>5 were considered to meet the criteria of sleep disturbance.

Time frame:
Baseline and 4 weeks
Reported as:
Mean · Percentage
Change From Baseline in Percent Activity Impairment Due to Sleep Disturbances (Average)
PercentageNexium 20 mgPlacebo
Change From Baseline in Percent Activity Impairment Due to Sleep Disturbances (Average)-25.1 ± 27.4-17.1 ± 28
SecondaryMonetary Value of Work Hours Saved

The monetary value of the work hours saved was derived from questions 2,4, and 5 of the WPAI and a standard hourly compensation rate reported by the US Bureau of Labor Statistics (US$28.48 as of June 2008).

Time frame:
Week 4
Reported as:
Least squares mean · Monetary value (US dollars)
Monetary Value of Work Hours Saved
Monetary value (US dollars)Nexium 20 mgPlacebo
Monetary Value of Work Hours Saved280.21 ± 34.88156.61 ± 33.05

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Nexium 20 mg—0/143 (0%)0/143 (0%)
Placebo—1/133 (0.8%)0/133 (0%)
Most frequent serious events
Most frequent serious events
EventNexium 20 mgPlacebo
PneumoniaInfections and infestations0/1431/133

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Nexium 20 mgPlaceboTotal
Mean47.0 ± 11.746.8 ± 12.946.9 ± 12.3
Sex: Female, Male
Sex: Female, Male(Participants)Nexium 20 mgPlaceboTotal
Female8985174
Male484088
08

Study locations

45 sites
  • Research Site
    Huntsville, Alabama, United States
  • Research Site
    Tucson, Arizona, United States
  • Research Site
    Little Rock, Arkansas, United States
  • Research Site
    Anaheim, California, United States
  • Research Site
    Burbank, California, United States
  • Research Site
    Castro Valley, California, United States
  • Research Site
    Orange, California, United States
  • Research Site
    San Diego, California, United States
  • Research Site
    Boynton Beach, Florida, United States
  • Research Site
    Coral SPrings, Florida, United States
  • Research Site
    Deland, Florida, United States
  • Research Site
    Hollywood, Florida, United States
  • Research Site
    Jupiter, Florida, United States
  • Research Site
    Pembroke Pines, Florida, United States
  • Research Site
    South Miami, Florida, United States
  • Research Site
    Tampa, Florida, United States
  • Research Site
    Zephyrhills, Florida, United States
  • Research Site
    Stockbridge, Georgia, United States
  • Research Site
    Overland Park, Kansas, United States
  • Research Site
    Lexington, Kentucky, United States
  • Research Site
    Hollywood, Maryland, United States
  • Research Site
    Las Vegas, Nevada, United States
  • Research Site
    Medford, New Jersey, United States
  • Research Site
    Perth Amboy, New Jersey, United States
  • Research Site
    West Orange, New Jersey, United States
  • Research Site
    Albuquerque, New Mexico, United States
  • Research Site
    Binghamton, New York, United States
  • Research Site
    Huntersville, North Carolina, United States
  • Research Site
    Raleigh, North Carolina, United States
  • Research Site
    Winston-Salem, North Carolina, United States
  • Research Site
    Cincinnati, Ohio, United States
  • Research Site
    Dayton, Ohio, United States
  • Research Site
    Kettering, Ohio, United States
  • Research Site
    Oklahoma City, Oklahoma, United States
  • Research Site
    Chattanooga, Tennessee, United States
  • Research Site
    Johnson City, Tennessee, United States
  • Research Site
    Amarillo, Texas, United States
  • Research Site
    Fort Worth Dallas, Texas, United States
  • Research Site
    Houston, Texas, United States
  • Research Site
    Ogden, Utah, United States
  • Research Site
    Burke, Virginia, United States
  • Research Site
    Christiansburg, Virginia, United States
  • Research Site
    Fredericksburg, Virginia, United States
  • Research Site
    Newport News, Virginia, United States
  • Research Site
    Bellevue, Washington, United States
09

References and documents

Publications

  • Johnson DA, Le Moigne A, Hugo V, Nagy P. Rapid resolution of sleep disturbances related to frequent reflux: effect of esomeprazole 20 mg in two randomized, double-blind, controlled trials. Curr Med Res Opin. 2015 Feb;31(2):243-50. doi: 10.1185/03007995.2014.991818. Epub 2015 Jan 9. PubMed 25478944 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2008, a primary completion of Jul 2008 and a completion of Jul 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2015, 6 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 15, 2008
First posted
Apr 17, 2008
Start
Apr 2008
Primary completionActual
Jul 2008
CompletionActual
Jul 2008
Results first posted
Mar 2, 2015
Last update
Mar 2, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00660660
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Apr 17, 2008
Start date
Apr 2008
Primary completion
Jul 2008
Completion
Jul 2008
Results posted
Mar 2, 2015
Last update
Mar 2, 2015

Study contacts

Tore Lind, MD
study director · AstraZeneca
Kurt Brown, MD
study director · AstraZeneca
David Johnson, MD
principal investigator · Eastern Virginia Medical School

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Esomeprazole

Start the discussion